These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33038141)

  • 1. Does age at the start of treatment for vaginal atrophy predict response to vaginal estrogen therapy? Post hoc analysis of data from a randomized clinical trial involving 205 women treated with 10 μg estradiol vaginal tablets.
    Derzko CM; Röhrich S; Panay N
    Menopause; 2020 Oct; 28(2):113-118. PubMed ID: 33038141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
    Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
    Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of estradiol vaginal gel on vaginal atrophy in postmenopausal women: A randomized double-blind controlled trial.
    Tanmahasamut P; Jirasawas T; Laiwejpithaya S; Areeswate C; Dangrat C; Silprasit K
    J Obstet Gynaecol Res; 2020 Aug; 46(8):1425-1435. PubMed ID: 32715556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
    Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA; Reape KZ; Wininger S; Hait H
    Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
    Fernandes T; Costa-Paiva LH; Pedro AO; Baccaro LF; Pinto-Neto AM
    Menopause; 2016 Jul; 23(7):792-8. PubMed ID: 27116462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial.
    Zohrabi I; Abedi P; Ansari S; Maraghi E; Shakiba Maram N; Houshmand G
    BMC Womens Health; 2020 May; 20(1):108. PubMed ID: 32429977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women.
    Mitchell CM; Guthrie KA; Larson J; Diem S; LaCroix AZ; Caan B; Shifren JL; Woods NF; Heiman JR; Lindau ST; Reed SD
    Menopause; 2019 Aug; 26(8):816-822. PubMed ID: 30994576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
    Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
    J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial.
    Bumphenkiatikul T; Panyakhamlerd K; Chatsuwan T; Ariyasriwatana C; Suwan A; Taweepolcharoen C; Taechakraichana N
    BMC Womens Health; 2020 Aug; 20(1):173. PubMed ID: 32787848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
    Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial.
    Mitchell CM; Reed SD; Diem S; Larson JC; Newton KM; Ensrud KE; LaCroix AZ; Caan B; Guthrie KA
    JAMA Intern Med; 2018 May; 178(5):681-690. PubMed ID: 29554173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study.
    Fernandes T; Pedro AO; Baccaro LF; Costa-Paiva LH
    Menopause; 2018 Jun; 25(6):641-647. PubMed ID: 29462095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
    Constantine GD; Bouchard C; Pickar JH; Archer DF; Graham S; Bernick B; Mirkin S
    J Womens Health (Larchmt); 2017 Jun; 26(6):616-623. PubMed ID: 28355090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of low-dose vaginal 17β-estradiol versus vaginal promestriene for vulvovaginal atrophy.
    Palacios S; Ramirez M; Lilue M
    Climacteric; 2022 Aug; 25(4):383-387. PubMed ID: 34813408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy.
    Portman D; Shulman L; Yeaw J; Zeng S; Uzoigwe C; Maamari R; Iyer NN
    Menopause; 2015 Nov; 22(11):1197-203. PubMed ID: 25944522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.